Andrada Pârvu, Iulia-Andrea Zsoldos and Anca Bojan
Anca Bojan, Bogdan Fetica, Bogdan Pop, Cătălin Vlad and Patriciu Achimaș-Cadariu
Tünde Tőrők-Vistai, Manuela Sfichi, Anca Bojan and Cristina Pojoga
Hepatitis C virus is known to be a risk factor for the development of B-cell non-Hodgkin lymphoma. Studies investigating the prevalence of hepatitis C virus in lymphoma report controversial results, depending on the geographical area. Monoclonal B lymphocytosis is an asymptomatic condition which can evolve into malignant lymphoma, characterized by the presence of a circulating clonal B population. It can be detected by flow cytometry and it is found at higher prevalence in hepatitis C virus-infected patients than in the general population. In the literature, there are only a few studies investigating its prevalence in hepatitis C infected patients and in Romania, such a study hasn’t been carried out before. We conducted a prospective study on 50 hepatitis C virus-infected patients from the Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor. Clinical and laboratory data were collected from the medical files. Flow cytometric analysis was carried out at the Immunology Department of the Emergency County Hospital Cluj Napoca. We have found a prevalence of 22% of monoclonal B lymphocytosis. There were no statistical differences between patients with or without monoclonality, except for the lower leucocyte count (p=0.04) and the more increased liver echogenicity in patients with monoclonality (p=0.02). All of the 3 subtypes of monoclonal B lymphocytosis were found. Increased prevalence of monoclonal B lymphocytosis in patients with hepatitis C virus infection sustains the virus role in lymphomagenesis, but further studies are needed to analyze the rate of transformation into lymphoma in these patients.
Anca Bojan, Ioana Berindan-Neagoe, S. Ciurea, Delia Dima, Shigeo Fuji, G. Ghiaur, Ravnit Grewal, Emmet Mccormack, Alina Tanase, A. Trifa and Ciprian Tomuleasa
In the March 2016 issue of the Lancet Haematology, the editorial office published a paper stating the roadmap for European research in hematology, based on the European Hematology Association (EHA) consensus document that outlines the directions in hematology for the following years across the continent. The meeting entitled “Insights in hematology” is organized a support for the initiative of a roadmap for European hematologists regarding research, may it be basic research or clinical research, but this consensus should not be focused mainly on European institutions, but rather form the backbone of global research between Europe and the United States, Japan or any other country. This will allow Europeans to learn as well as to share their experience with the rest of the scientific and medical community. And the Cluj-Napoca meeting should be followed by other such meetings all across the EU.
C. Lucan, Laura-Ancuta Pop, A. Florian, Valentina Pileczki, B. Petrushev, Delia Dima, Ioana Frinc, Ioana Berindan-Neagoe, A. Irimie, C. Berce, I.-S. Florian, Anca Bojan and C. Tomuleasa
From an oncological perspective, the second most common malignancies in children are brain tumors. Despite the recent therapeutic breakthroughs in this field, concerning surgery, radiotherapy and chemotherapy alike, some cases still have poor outcomes in curability. This is especially the case in patients with high-risk histological types of tumors, and those suffering from residual, remitting and disseminated diseases. Due to the unique neuroanatomical emplacement of brain tumors and their aggressive infiltrative behavior, their total removal remains a demanding task. This can be perceived in the high rates of failure treatment and disease recurrence. Furthermore, the adjacent healthy brain tissue is inevitably damaged in the surgical process of effectively removing these tumors. Thus, stem cell transplantation may be a viable solution for the clinical management of these malignancies, as proven by various recent breakthroughs. In the current concise review, we present the role of next generation sequencing in HLA typing for stem cell transplantation in primary CNS pediatric malignancies.
Ioana Frinc, Petru Ilies, Florin Zaharie, Delia Dima, Alina Tanase, Ljubomir Petrov, Alexandru Irimie, Cristian Berce, Cosmin Lisencu, Ioana Berindan-Neagoe, Ciprian Tomuleasa and Anca Bojan
In the past decade, there has been significant progress in clinical hematology with the discovery of targeted molecules and thus the achievement of both hematologic and molecular responses. Nevertheless, chemotherapy remains the treatment of choice for many types of hematological malignancies. Aggressive chemotherapy leads to immunosuppression, accompanied by a high rate of infections and an increased rate of treatment-related mortality. Invasive fungal infections as well as more common bacterial and viral infections are frequent in immunocompromised patients as they are difficult to diagnose and treat. Pleuropulmonary infections in immunocompromised patients are diagnosed using clinical examination, imaging and laboratory tests. Many laboratory tests are run for several days before a final result is given and are expensive. Computer tomography is a reliable technique, but it is encumbered by high irradiation and high cost, and can assess lesions larger than 1 cm. Transthoracic ultrasound is a modern method, used in the diagnostic algorithm of pleuropulmonary pathology. It allows the diagnosis of small lesions, can be performed at the patients’ bedside, with acceptable costs and no irradiation. A fast, informed and accurate medical decision is essential for a favorable outcome in immunosuppressed patients with an adjacent infection. In the current case series we present the implementation of a new protocol for the follow-up of immunocompromised patients using transthoracic ultrasonography, of great potential use in the clinic.